Nonsurgical Approach to Treat Post-Rhinoplasty Vascular Complication With Hyaluronic Acid Injection.

Journal of cosmetic dermatology 2025 Vol.24(7) p. e70294

Qiang S, Fan X, Yin Y, Xue P, Dou WJ, Li T, Yang Q

관련 도메인

Abstract

[BACKGROUND] Hyaluronic acid (HA) fillers are popular for their minimally invasive nature and immediate aesthetic outcomes, but vascular compromise remains a significant complication. This study investigates optimized therapeutic strategies to prevent tissue necrosis following HA filler injections.

[AIMS] To evaluate the efficacy of two treatment regimens for managing impending nasal skin necrosis due to HA filler injections, focusing on preventing tissue necrosis and reducing complications such as pigmentation changes, scarring, and telangiectasia.

[PATIENTS AND METHODS] A retrospective analysis was conducted on 41 female patients (mean age: 36.2 years) treated at a single referral center between 2018 and 2023. Patients presented within 72 h after developing ischemic symptoms following HA injections for nasal augmentation. Two treatment regimens, both integrating hyperbaric oxygen therapy (HBOT), epidermal growth factor (EGF) gel, and corticosteroids, were evaluated: one using nitroglycerin (NTG) and the other using isosorbide dinitrate (ISDN).

[RESULTS] All patients achieved complete wound healing, with no significant differences in scar formation or hypotension between the treatment groups (p > 0.05). Hyaluronidase (HSE) was administered externally at referring clinics prior to hospital admission in 31.7% of patients (without subsequent standardized HSE protocol), significantly reducing telangiectasia incidence (p < 0.05) but not affecting scarring or pigmentation (p > 0.05). Early hospital presentation (< 48 h) was associated with lower pigmentation changes (p < 0.05) but did not significantly affect scarring. Residual complications included scar formation in 9 of 41 patients (21.9%, 95% CI 12.0-36.7), telangiectasia in 16 of 41 (39.0%, 95% CI 25.7-54.3), and pigmentation changes in 22 of 41 (53.7%, 95% CI 38.7-67.9).

[CONCLUSIONS] Combined therapies effectively manage HA-induced vascular compromise, with early intervention critical for reducing ischemic complications and improving patient outcomes.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
재료 ha 히알루론산 dict 5
합병증 pigmentation 색소침착 dict 4
시술 ha filler 필러 주입술 dict 2
합병증 tissue necrosis 괴사 dict 2
합병증 vascular compromise 혈관폐색 dict 2
재료 hyaluronic acid 히알루론산 dict 2
시술 rhinoplasty 코성형술 dict 1
해부 tissue scispacy 1
합병증 nasal skin scispacy 1
합병증 wound scispacy 1
합병증 scar scispacy 1
합병증 skin necrosis 괴사 dict 1
약물 [BACKGROUND] Hyaluronic acid scispacy 1
약물 36.2 scispacy 1
약물 hyperbaric oxygen scispacy 1
약물 HBOT → hyperbaric oxygen therapy scispacy 1
약물 corticosteroids scispacy 1
약물 isosorbide scispacy 1
약물 CI 25.7 scispacy 1
약물 [CONCLUSIONS] scispacy 1
약물 oxygen C0030054
oxygen
scispacy 1
약물 nitroglycerin C0017887
nitroglycerin
scispacy 1
약물 NTG → nitroglycerin C0017887
nitroglycerin
scispacy 1
약물 isosorbide dinitrate C0022252
isosorbide dinitrate
scispacy 1
약물 ISDN → isosorbide dinitrate C0022252
isosorbide dinitrate
scispacy 1
질환 hypotension C0020649
Hypotension
scispacy 1
질환 HSE → Hyaluronidase scispacy 1
질환 necrosis C0027540
Necrosis
scispacy 1
질환 nasal skin necrosis scispacy 1
질환 telangiectasia C0039446
Telangiectasis
scispacy 1
기타 Post-Rhinoplasty Vascular scispacy 1
기타 vascular scispacy 1
기타 patients scispacy 1
기타 nasal scispacy 1
기타 epidermal growth factor scispacy 1
기타 EGF → epidermal growth factor scispacy 1
기타 patient scispacy 1

MeSH Terms

Humans; Female; Hyaluronic Acid; Adult; Retrospective Studies; Dermal Fillers; Hyperbaric Oxygenation; Hyaluronoglucosaminidase; Rhinoplasty; Middle Aged; Nitroglycerin; Telangiectasis; Necrosis; Skin; Treatment Outcome; Ischemia; Vasodilator Agents; Young Adult; Adrenal Cortex Hormones; Combined Modality Therapy

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문